Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1258

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 5
Chunk 1258
---
(7,955,663) 
     (3,813,800)
  
    Net Loss  – Noncontrolling Interest 
     (8,556) 
     (48,098)
  
    Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. 
    $(7,947,107) 
    $(3,765,702)

48

The following table sets forth our results of
operations as a percentage of revenue:

    For the Year Ended
    December 31, 
  
    Consolidated Statements of Operations Data: 
    2024  
    2023 
  
    Product Revenues – net of Discounts and Rebates 
     100.00% 
     100.00%
  
    Cost of Revenues 
     63.33  
     187.15 
  
    Gross Profit (Loss) 
     36.67  
     (87.15)
  
    Research Revenues 
     12.14  
     - 
  
    Net Revenue (Loss) 
     48.81  
     (87.15)

    Operating Expenses: 

    Research and Development 
     820.73  
     272.81 
  
    General and Administrative Expenses 
     827.06  
     1,672.83 
  
    Total Operating Expenses 
     1,647.78  
     1,945.64 

    Loss from Operations 
     (1,598.97) 
     (2,032.78)

    Interest Expense 
     (1.30) 
     (901.77)
  
    Derivative Expense 
     -  
     (157.64)
  
    Change in Fair Value of Derivative Liabilities 
     274.20  
     (14.70)
  
    Loss on Debt Extinguishment 
     -  
     (485.65)
  
    Change in Fair Value of Promissory Note 
     -  
     2,121.39 
  
    Other Income (Expense), net 
     16.70  
     (32.78)
  
    Total Interest and Other Income (Expense), net 
     289.60  
     528.85 
  
    Loss from Operations before Provision for Income Taxes 
     (1,309.37) 
     (1,